Tempus (Nasdaq: TEM) Earnings: Live Coverage And What to Expect
Live Updates Live Coverage Updates appear automatically as they are published. Tempus consensus estimates 10:40 am by Joel South Q1 2025 Revenue: $248.1 million GAAP EPS Estimate: $(0.27) Adjusted EBITDA: $(21.7 million) Gross Margin: 58.8% FY2025 Revenue Guidance: $1.24 billion Average Analyst Price Target: $61.40 Range: $48.00 – $74.00 Expectations imply steep topline growth and […] The post Tempus (Nasdaq: TEM) Earnings: Live Coverage And What to Expect appeared first on 24/7 Wall St..
Live Updates
Updates appear automatically as they are published.
Tempus consensus estimates
-
Q1 2025 Revenue: $248.1 million
-
GAAP EPS Estimate: $(0.27)
-
Adjusted EBITDA: $(21.7 million)
-
Gross Margin: 58.8%
-
FY2025 Revenue Guidance: $1.24 billion
-
Average Analyst Price Target: $61.40
-
Range: $48.00 – $74.00
-
Expectations imply steep topline growth and widening platform adoption, with close attention on EBITDA progress and contract retention.
What to watch when earnings drop
Tempus AI enters Q1 2025 earnings riding strong investor momentum, with shares up over 80% in the past six months, according to recent trading data. The company has benefited from heightened interest in AI-powered healthcare tools and real-world evidence platforms, especially among institutional buyers in biotech and digital health.
Recent announcements highlight partnerships with academic medical centers and global pharmaceutical firms, helping Tempus expand both its clinical testing volumes and enterprise software footprint. Analysts are closely watching churn metrics, net revenue retention, and traction in the biopharma SaaS segment, which has become a key pillar of growth.
While optimism is high, the company’s valuation — over 20x forward revenue — puts pressure on execution. Investors will look for confirmation that Tempus is converting pilot projects into recurring, high-margin contracts, and expanding its platform internationally with sustainable economics.
Tempus AI (NASDAQ: TEM), a fast-rising player in clinical AI and health data infrastructure, will report its Q1 2025 earnings after the market closes today. Analysts expect revenue of $248.1 million and a GAAP EPS loss of $(0.27), according to Capital IQ consensus.
Founded by Eric Lefkofsky, Tempus has positioned itself as a central data and intelligence platform across oncology, rare diseases, and life sciences research. Its proprietary datasets and AI-driven diagnostics are used by clinicians to inform real-time treatment decisions, while pharmaceutical clients leverage Tempus for trial recruitment, biomarker discovery, and real-world evidence insights.
For Q1, investors will be watching for continued traction across Tempus’ three core commercial segments — clinical testing, pharma SaaS, and data licensing. Analysts also expect commentary around enterprise renewals and the company’s expanding international partnerships, including recent deployments in the European Union.
Guidance will be in sharp focus. The company reaffirmed full-year 2025 revenue guidance of $1.24 billion, implying nearly 78% year-over-year growth. Gross margin is projected at 58.8%, and any signals of operating leverage will be key to sustaining the stock’s elevated valuation.
The post Tempus (Nasdaq: TEM) Earnings: Live Coverage And What to Expect appeared first on 24/7 Wall St..
